Polymyositis Treatment Market - Global Outlook and Forecast 2022-2028

March 2022 | 67 pages | ID: P502BB6D80EBEN
Market Monitor Global

Abstracts

Polymyositis (PM) is a type of chronic inflammation of the muscles (inflammatory myopathy) related to dermatomyositis and inclusion body myositis. Its name means 'inflammation of many muscles' (poly- + myos- + -itis).

This report contains market size and forecasts of Polymyositis Treatment in Global, including the following market information:

Global Polymyositis Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Polymyositis Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Immunosuppressant Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Polymyositis Treatment include Hospira, Inc., Antares Pharma, Inc., Medexus Pharma, Inc., Fresenius SE & Co. KGaA, Mylan N.V., Alcami Corporation, Teva Pharmaceuticals, Novartis AG and Genentech, Inc.. etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Polymyositis Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Polymyositis Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Polymyositis Treatment Market Segment Percentages, by Type, 2021 (%)

• Immunosuppressant
• Alkylating Agent
• Immunoglobulin
• Monoclonal Antibodies
• Corticosteroids

Global Polymyositis Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Polymyositis Treatment Market Segment Percentages, by Application, 2021 (%)

• Hospitals
• Clinic
• Others

Global Polymyositis Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Polymyositis Treatment Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Polymyositis Treatment revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Polymyositis Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Hospira, Inc.
• Antares Pharma, Inc.
• Medexus Pharma, Inc.
• Fresenius SE & Co. KGaA
• Mylan N.V.
• Alcami Corporation
• Teva Pharmaceuticals
• Novartis AG
• Genentech, Inc.

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Polymyositis Treatment Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Polymyositis Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL POLYMYOSITIS TREATMENT OVERALL MARKET SIZE

2.1 Global Polymyositis Treatment Market Size: 2021 VS 2028
2.2 Global Polymyositis Treatment Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Polymyositis Treatment Players in Global Market
3.2 Top Global Polymyositis Treatment Companies Ranked by Revenue
3.3 Global Polymyositis Treatment Revenue by Companies
3.4 Top 3 and Top 5 Polymyositis Treatment Companies in Global Market, by Revenue in 2021
3.5 Global Companies Polymyositis Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Polymyositis Treatment Players in Global Market
  3.6.1 List of Global Tier 1 Polymyositis Treatment Companies
  3.6.2 List of Global Tier 2 and Tier 3 Polymyositis Treatment Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Polymyositis Treatment Market Size Markets, 2021 & 2028
  4.1.2 Immunosuppressant
  4.1.3 Alkylating Agent
  4.1.4 Immunoglobulin
  4.1.5 Monoclonal Antibodies
  4.1.6 Corticosteroids
4.2 By Type - Global Polymyositis Treatment Revenue & Forecasts
  4.2.1 By Type - Global Polymyositis Treatment Revenue, 2017-2022
  4.2.2 By Type - Global Polymyositis Treatment Revenue, 2023-2028
  4.2.3 By Type - Global Polymyositis Treatment Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Polymyositis Treatment Market Size, 2021 & 2028
  5.1.2 Hospitals
  5.1.3 Clinic
  5.1.4 Others
5.2 By Application - Global Polymyositis Treatment Revenue & Forecasts
  5.2.1 By Application - Global Polymyositis Treatment Revenue, 2017-2022
  5.2.2 By Application - Global Polymyositis Treatment Revenue, 2023-2028
  5.2.3 By Application - Global Polymyositis Treatment Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Polymyositis Treatment Market Size, 2021 & 2028
6.2 By Region - Global Polymyositis Treatment Revenue & Forecasts
  6.2.1 By Region - Global Polymyositis Treatment Revenue, 2017-2022
  6.2.2 By Region - Global Polymyositis Treatment Revenue, 2023-2028
  6.2.3 By Region - Global Polymyositis Treatment Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Polymyositis Treatment Revenue, 2017-2028
  6.3.2 US Polymyositis Treatment Market Size, 2017-2028
  6.3.3 Canada Polymyositis Treatment Market Size, 2017-2028
  6.3.4 Mexico Polymyositis Treatment Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Polymyositis Treatment Revenue, 2017-2028
  6.4.2 Germany Polymyositis Treatment Market Size, 2017-2028
  6.4.3 France Polymyositis Treatment Market Size, 2017-2028
  6.4.4 U.K. Polymyositis Treatment Market Size, 2017-2028
  6.4.5 Italy Polymyositis Treatment Market Size, 2017-2028
  6.4.6 Russia Polymyositis Treatment Market Size, 2017-2028
  6.4.7 Nordic Countries Polymyositis Treatment Market Size, 2017-2028
  6.4.8 Benelux Polymyositis Treatment Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Polymyositis Treatment Revenue, 2017-2028
  6.5.2 China Polymyositis Treatment Market Size, 2017-2028
  6.5.3 Japan Polymyositis Treatment Market Size, 2017-2028
  6.5.4 South Korea Polymyositis Treatment Market Size, 2017-2028
  6.5.5 Southeast Asia Polymyositis Treatment Market Size, 2017-2028
  6.5.6 India Polymyositis Treatment Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Polymyositis Treatment Revenue, 2017-2028
  6.6.2 Brazil Polymyositis Treatment Market Size, 2017-2028
  6.6.3 Argentina Polymyositis Treatment Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Polymyositis Treatment Revenue, 2017-2028
  6.7.2 Turkey Polymyositis Treatment Market Size, 2017-2028
  6.7.3 Israel Polymyositis Treatment Market Size, 2017-2028
  6.7.4 Saudi Arabia Polymyositis Treatment Market Size, 2017-2028
  6.7.5 UAE Polymyositis Treatment Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Hospira, Inc.
  7.1.1 Hospira, Inc. Corporate Summary
  7.1.2 Hospira, Inc. Business Overview
  7.1.3 Hospira, Inc. Polymyositis Treatment Major Product Offerings
  7.1.4 Hospira, Inc. Polymyositis Treatment Revenue in Global Market (2017-2022)
  7.1.5 Hospira, Inc. Key News
7.2 Antares Pharma, Inc.
  7.2.1 Antares Pharma, Inc. Corporate Summary
  7.2.2 Antares Pharma, Inc. Business Overview
  7.2.3 Antares Pharma, Inc. Polymyositis Treatment Major Product Offerings
  7.2.4 Antares Pharma, Inc. Polymyositis Treatment Revenue in Global Market (2017-2022)
  7.2.5 Antares Pharma, Inc. Key News
7.3 Medexus Pharma, Inc.
  7.3.1 Medexus Pharma, Inc. Corporate Summary
  7.3.2 Medexus Pharma, Inc. Business Overview
  7.3.3 Medexus Pharma, Inc. Polymyositis Treatment Major Product Offerings
  7.3.4 Medexus Pharma, Inc. Polymyositis Treatment Revenue in Global Market (2017-2022)
  7.3.5 Medexus Pharma, Inc. Key News
7.4 Fresenius SE & Co. KGaA
  7.4.1 Fresenius SE & Co. KGaA Corporate Summary
  7.4.2 Fresenius SE & Co. KGaA Business Overview
  7.4.3 Fresenius SE & Co. KGaA Polymyositis Treatment Major Product Offerings
  7.4.4 Fresenius SE & Co. KGaA Polymyositis Treatment Revenue in Global Market (2017-2022)
  7.4.5 Fresenius SE & Co. KGaA Key News
7.5 Mylan N.V.
  7.5.1 Mylan N.V. Corporate Summary
  7.5.2 Mylan N.V. Business Overview
  7.5.3 Mylan N.V. Polymyositis Treatment Major Product Offerings
  7.5.4 Mylan N.V. Polymyositis Treatment Revenue in Global Market (2017-2022)
  7.5.5 Mylan N.V. Key News
7.6 Alcami Corporation
  7.6.1 Alcami Corporation Corporate Summary
  7.6.2 Alcami Corporation Business Overview
  7.6.3 Alcami Corporation Polymyositis Treatment Major Product Offerings
  7.6.4 Alcami Corporation Polymyositis Treatment Revenue in Global Market (2017-2022)
  7.6.5 Alcami Corporation Key News
7.7 Teva Pharmaceuticals
  7.7.1 Teva Pharmaceuticals Corporate Summary
  7.7.2 Teva Pharmaceuticals Business Overview
  7.7.3 Teva Pharmaceuticals Polymyositis Treatment Major Product Offerings
  7.7.4 Teva Pharmaceuticals Polymyositis Treatment Revenue in Global Market (2017-2022)
  7.7.5 Teva Pharmaceuticals Key News
7.8 Novartis AG
  7.8.1 Novartis AG Corporate Summary
  7.8.2 Novartis AG Business Overview
  7.8.3 Novartis AG Polymyositis Treatment Major Product Offerings
  7.8.4 Novartis AG Polymyositis Treatment Revenue in Global Market (2017-2022)
  7.8.5 Novartis AG Key News
7.9 Genentech, Inc.
  7.9.1 Genentech, Inc. Corporate Summary
  7.9.2 Genentech, Inc. Business Overview
  7.9.3 Genentech, Inc. Polymyositis Treatment Major Product Offerings
  7.9.4 Genentech, Inc. Polymyositis Treatment Revenue in Global Market (2017-2022)
  7.9.5 Genentech, Inc. Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Polymyositis Treatment Market Opportunities & Trends in Global Market
Table 2. Polymyositis Treatment Market Drivers in Global Market
Table 3. Polymyositis Treatment Market Restraints in Global Market
Table 4. Key Players of Polymyositis Treatment in Global Market
Table 5. Top Polymyositis Treatment Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Polymyositis Treatment Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Polymyositis Treatment Revenue Share by Companies, 2017-2022
Table 8. Global Companies Polymyositis Treatment Product Type
Table 9. List of Global Tier 1 Polymyositis Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Polymyositis Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Polymyositis Treatment Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Polymyositis Treatment Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Polymyositis Treatment Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Polymyositis Treatment Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Polymyositis Treatment Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Polymyositis Treatment Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Polymyositis Treatment Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Polymyositis Treatment Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Polymyositis Treatment Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Polymyositis Treatment Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Polymyositis Treatment Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Polymyositis Treatment Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Polymyositis Treatment Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Polymyositis Treatment Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Polymyositis Treatment Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Polymyositis Treatment Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Polymyositis Treatment Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Polymyositis Treatment Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Polymyositis Treatment Revenue, (US$, Mn), 2023-2028
Table 30. Hospira, Inc. Corporate Summary
Table 31. Hospira, Inc. Polymyositis Treatment Product Offerings
Table 32. Hospira, Inc. Polymyositis Treatment Revenue (US$, Mn), (2017-2022)
Table 33. Antares Pharma, Inc. Corporate Summary
Table 34. Antares Pharma, Inc. Polymyositis Treatment Product Offerings
Table 35. Antares Pharma, Inc. Polymyositis Treatment Revenue (US$, Mn), (2017-2022)
Table 36. Medexus Pharma, Inc. Corporate Summary
Table 37. Medexus Pharma, Inc. Polymyositis Treatment Product Offerings
Table 38. Medexus Pharma, Inc. Polymyositis Treatment Revenue (US$, Mn), (2017-2022)
Table 39. Fresenius SE & Co. KGaA Corporate Summary
Table 40. Fresenius SE & Co. KGaA Polymyositis Treatment Product Offerings
Table 41. Fresenius SE & Co. KGaA Polymyositis Treatment Revenue (US$, Mn), (2017-2022)
Table 42. Mylan N.V. Corporate Summary
Table 43. Mylan N.V. Polymyositis Treatment Product Offerings
Table 44. Mylan N.V. Polymyositis Treatment Revenue (US$, Mn), (2017-2022)
Table 45. Alcami Corporation Corporate Summary
Table 46. Alcami Corporation Polymyositis Treatment Product Offerings
Table 47. Alcami Corporation Polymyositis Treatment Revenue (US$, Mn), (2017-2022)
Table 48. Teva Pharmaceuticals Corporate Summary
Table 49. Teva Pharmaceuticals Polymyositis Treatment Product Offerings
Table 50. Teva Pharmaceuticals Polymyositis Treatment Revenue (US$, Mn), (2017-2022)
Table 51. Novartis AG Corporate Summary
Table 52. Novartis AG Polymyositis Treatment Product Offerings
Table 53. Novartis AG Polymyositis Treatment Revenue (US$, Mn), (2017-2022)
Table 54. Genentech, Inc. Corporate Summary
Table 55. Genentech, Inc. Polymyositis Treatment Product Offerings
Table 56. Genentech, Inc. Polymyositis Treatment Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Polymyositis Treatment Segment by Type in 2021
Figure 2. Polymyositis Treatment Segment by Application in 2021
Figure 3. Global Polymyositis Treatment Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Polymyositis Treatment Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Polymyositis Treatment Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Polymyositis Treatment Revenue in 2021
Figure 8. By Type - Global Polymyositis Treatment Revenue Market Share, 2017-2028
Figure 9. By Application - Global Polymyositis Treatment Revenue Market Share, 2017-2028
Figure 10. By Region - Global Polymyositis Treatment Revenue Market Share, 2017-2028
Figure 11. By Country - North America Polymyositis Treatment Revenue Market Share, 2017-2028
Figure 12. US Polymyositis Treatment Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Polymyositis Treatment Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Polymyositis Treatment Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Polymyositis Treatment Revenue Market Share, 2017-2028
Figure 16. Germany Polymyositis Treatment Revenue, (US$, Mn), 2017-2028
Figure 17. France Polymyositis Treatment Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Polymyositis Treatment Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Polymyositis Treatment Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Polymyositis Treatment Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Polymyositis Treatment Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Polymyositis Treatment Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Polymyositis Treatment Revenue Market Share, 2017-2028
Figure 24. China Polymyositis Treatment Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Polymyositis Treatment Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Polymyositis Treatment Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Polymyositis Treatment Revenue, (US$, Mn), 2017-2028
Figure 28. India Polymyositis Treatment Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Polymyositis Treatment Revenue Market Share, 2017-2028
Figure 30. Brazil Polymyositis Treatment Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Polymyositis Treatment Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Polymyositis Treatment Revenue Market Share, 2017-2028
Figure 33. Turkey Polymyositis Treatment Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Polymyositis Treatment Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Polymyositis Treatment Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Polymyositis Treatment Revenue, (US$, Mn), 2017-2028
Figure 37. Hospira, Inc. Polymyositis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Antares Pharma, Inc. Polymyositis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Medexus Pharma, Inc. Polymyositis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Fresenius SE & Co. KGaA Polymyositis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Mylan N.V. Polymyositis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Alcami Corporation Polymyositis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Teva Pharmaceuticals Polymyositis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Novartis AG Polymyositis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Genentech, Inc. Polymyositis Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)